Development, validation and implementation of immobilized metal affinity for phosphochemicals (IMAP)-based high-throughput screening assays for low-molecular-weight compound libraries

Nature Protocols

Volumn 3, Issue 8, 2008, Pages 1350-1363

  Sharlow, Elizabeth R ^a   Leimgruber, Stephanie ^a   Yellow Duke, Archibong ^a   Barrett, Rebecca ^a   Wang, Qiming Jane ^a   Lazo, John S ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; BUFFER; PHOSPHOTRANSFERASE INHIBITOR;

ARTICLE; AUTOMATION; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG SCREENING; ENZYME MECHANISM; ENZYME STABILITY; ENZYME SUBSTRATE COMPLEX; HIGH THROUGHPUT SCREENING; HUMAN; IMMOBILIZED METAL AFFINITY FOR PHOSPHOCHEMICALS BASED FLUORESCENCE POLARIZATION; MOLECULAR WEIGHT; PRIORITY JOURNAL; TIME RESOLVED FLUORESCENCE RESONANCE ENERGY TRANSFER; VALIDATION PROCESS;

CELL CYCLE PROTEINS; ENZYME STABILITY; FLUORESCENCE POLARIZATION; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMANS; INHIBITORY CONCENTRATION 50; PHOSPHOTRANSFERASES; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; SMALL MOLECULE LIBRARIES;

EID: 50349102135     PISSN: 17542189     EISSN: 17502799     Source Type: Journal    
DOI: 10.1038/nprot.2008.111     Document Type: Article

References (55)

1. Inglese, J. et al. High-throughput screening assays for the identification of chemical probes. Nat. Chem. Biol. 3, 466-479 (2007).
2. Hertzberg, R.P. & Pope, A.J. High-throughput screening: New technology for the 21st century. Curr. Opin. Chem. Biol. 4, 445-451 (2000).
3. Trinquet, E. & Mathis, G. Fluorescence technologies for the investigation of chemical libraries. Mol. BioSyst. 2, 380-387 (2006).
4. Pereira, D.A. & Williams, J.A. Origin and evolution of high throughput screening. Br. J. Pharmacol. 152, 53-61 (2007).
5. Fox, S. et al. High-throughput screening: Update of practices and success. J. Biomol. Screen. 11, 864-869 (2006).
6. Verkman, A.S. Drug discovery in academia. Am. J. Physiol. Cell Physiol. 286, C465-C474 (2004).
7. Austin, C.P., Brady, L.S., Insel, T.R. & Collins, F.S. NIH Molecular Libraries Initiative. Science 306, 1138-1139 (2004).
8. Lazo, J.S. Roadmap or roadkill: A pharmacologist's analysis of the NIH Molecular Libraries Initiative. Mol. Interv. 6, 240-241 (2006).
9. Nwaka, S. & Hudson, A. Innovative lead discovery strategies for tropical diseases. Nat. Rev. Drug Discov. 5, 941-955 (2006).
10. Madoux, F. et al. Potent, selective and cell penetrant inhibitors of SF-1 by functional uHTS. Mol. Pharmacol. 73, 1776-1784 (2008).
11. Sharlow, E.R., Leimgruber, S.S., Shun, T.Y. & Lazo, J.S. Development and implementation of miniaturized high throughput time-resolved fluorescence energy transfer assay to identify small molecule inhibitors of polo-like kinase 1. Assay Drug Dev. Technol. 5, 723-735 (2007).
12. Blume-Jensen, P. & Hunter, T. Oncogenic kinase signaling. Nature 411, 355-365 (2001).
13. Cohen, P. Protein kinases - the major drug targets of the twenty-first century. Nat. Rev. Drug Discov. 1, 309-315 (2002).
14. Manning, G., Whyte, D.B., Martinez, R., Hunter, T. & Sudarsanam, S. The protein kinase complement of the human genome. Science 298, 1912-1934 (2002).
15. Gribbon, P. & Sewing, A. Fluorescence readouts in HTS: No gain without pain? Drug Discov. Today 8, 1035-1043 (2003).
16. Munagala, N. et al. Identification of small molecule ceramide kinase inhibitors using a homogeneous chemiluminescence high throughput assay. Assay Drug Dev. Technol. 5, 65-73 (2007).
17. Koresawa, M. & Okabe, T. High-throughput screening with quantitation of ATP consumption: A universal non-radioisotope homogeneous assay for protein kinase. Assay Drug Dev. Technol. 2, 153-160 (2004).
18. Rykx, A. et al. An enzyme-linked immunosorbent assay for protein kinase D activity using phosphorylation site-specific antibodies. Assay Drug Dev. Technol. 5, 637-643 (2007).
19. Togame, H., Fuchikami, K., Sagara, A., Inbe, H. & Ziegelbauer, K. Development of a non-radioactive, 384-well format assay to detect inhibitors of the mitogen-activated protein kinase kinase 4. Assay Drug Dev. Technol. 3, 65-76 (2005).
20. Eggeling, C., Brand, L., Ullmann, D. & Jager, S. Highly sensitive fluorescence detection technology currently available for HTS. Drug Discov. Today 8, 632-641 (2003).
21. Mallari, R. et al. A generic high-throughput screening assay for kinases: Protein kinase A as an example. J. Biomol. Screen. 8 198-204 (2003).
22. Pope, A.J., Haupts, U.M. & Moore, K.J. Homogenous fluorescence readouts for miniaturized high-throughput screening: Theory and practice. Drug Discov. Today 4, 350-362 (1999). 7
23. Kristjansdottir, K. & Rudolph, J. A fluorescence polarization assay for native protein substrates of kinases. Anal. Biochem. 316, 41-49 (2003).
24. Huss, K.L., Blonigen, P.E. & Campbell, R.M. Development of a Transcreener kinase assay for protein kinase A and demonstration of concordance of data with a filter-binding assay format. J. Biomol. Screen. 12, 578-584 (2007).
25. Schröter, T. et al. Comparison of miniaturized time-resolved fluorescence resonance energy transfer and enzyme-coupled luciferase high-throughput screening assays to discover inhibitors of Rho-kinase II (ROCK II). J. Biomol. Screen. 13, 17-28 (2008).
26. Kashem et al. Three mechanistically distinct kinase assays compared: Measurements of intrinsic ATPase activity identified the most comprehensive set of ITK inhibitors. J. Biomol. Screen. 12, 70-83 (2007).
27. Von Ahsen, O., Schmidt, A., Klotz, M. & Parczyk, K. Assay concordance between SPA and TR-FRET in high-throughput screening. J. Biomol. Screen. 11, 606-616 (2006).
28. Kadkhodayan, S. et al. Evaluation of assay technologies for the identification of protein-peptide interaction antagonists. Assay Drug Dev. Technol. 5, 501-513 (2007).
29. Rininsland, F. et al. Metal ion-mediated polymer superquenching for highly sensitive defection of kinase and phosphatase activities. Proc. Natl. Acad. Sci. USA 101, 15295-15300 (2004).
30. Comley, J. Assay interference - a limiting factor in HTS. Drug Discov. World Summer 91-98 (2003).
31. Gaudet, E.A. et al. A homogeneous fluorescence polarization assay adaptable for a range of protein serine/threonine and tyrosine kinases. J. Biomol. Screen. 8, 164-175 (2003).
32. Sportsman, J.R., Gaudet, E.A. & Broge, A. Immobilized metal ion affinity-based fluorescence polarization (IMAP): Advance in kinase screening. Assay Drug Dev. Technol. 2, 205-214 (2004).
33. Loomans, E.E., van Doommalen, A.M., Wat, J.W. & Zaman, G.J. High-throughput screening with immobilized metal ion affinity-based fluorescence polarization detection, a homogeneous assay for protein kinases. Assay Diug Dev. Technol. 1, 445-453 (2003).
34. Banks, P. & Harvey, M. Considerations for using fluorescence polarization in the screening of G protein-coupled receptors. J. Biomol. Screen. 7, 111-117 (2002).
35. Sportsman, R. & Gaudet, E. IMAP: Detection and quantification of kinase inhibitors. IMAP application Misc: Note number 2 http://www.moleculardevices.com/ (2004).
36. Turek-Etienne, T.C., Kober, T.P., Stafford, J.M. & Bryant, R.W. Development of a fluorescence polarization AKT serine/threonine kinase assay using an immobilized metal ion affinity-based technology. Assay Drug Dev. Technol. 1, 545-553 (2003).
37. Klumpp, M. et al. Readout technologies for highly miniaturized kinase assays applicable to high-throughput screening in a 1536-well format. J. Biomol. Screen. 11, 617-633 (2006).
38. Lu, Z. et al. Development of a fluorescence polarization bead-based coupled assay to target different activity/conformation states of a protein kinase. J. Biomol. Screen. 9, 309-321 (2004).
39. Comley, J. TR-FRET based assays - getting better with age. Drug Discov. World Spring 22-37 (2006).
40. Strebhardt, K. & Ullrich, A. Targeting polo-like kinase 1 for cancer therapy. Nat. Rev. Cancer 6, 321-330 (2006).
41. Guimreddy, K. et al. ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. Cancer Cell 7 275-286 (2005).
42. Steegmaier, M. et al. BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr. Biol. 17, 316-322 (2007).
43. Wang, Q.J. PKD at the crossroads of DAG and PKC signaling. Trends Pharmacol. Sci. 27, 317-323 (2006).
44. Avkiran, M., Rowland, A.J., Cuello, F. & Haworth, R.S. Protein kinase D in the cardiovascular system: Emerging roles in health and disease. Circ. Res. 102, 157-163 (2008).
45. Brisson Tiemo, M. et al. Development and optimization of high-throughput in vitro protein phosphatase screening assays. Nat. Protoc. 2, 1134-1143 (2007).
46. Boge, A. TR-FRET detection with IMAP. IMAP application note number 7. http://www.moleculardevices.com/ (2007).
47. Wu, G., Yuan, Y. & Hodge, C.N. Determining appropriate substrate conversion for enzymatic assays in high-throughput screening. J. Biomol. Screen. 8, 694-700 (2003).
48. Macarrón, R. & Hertzberg, R.P. Design and implementation of high throughput screening assays. Methods Mol. Biol. 190, 1-29 (2002).
49. Duan, W. et al. Establishment and application of a high throughput model for rho kinase inhibitors screening based on fluorescence polarization. Biol. Pharm. Bull. 29, 1138-1142 (2006).
50. Huang, W., Zhang, Y. & Sportsman, J.R. A fluorescence polarization assay for cyclic nucleotide phosphodiesterases. J. Biomol. Screen. 7 215-222 (2002).
51. Beasley, J.R., McCoy, P.M., Walker, T.L. & Dunn, D.A. Miniaturized, ultra high throughput screening of tyrosine kinases using homogeneous, competitive fluorescence immunoassays. Assay Drug Dev. Technol. 2, 141-151 (2003).
52. Zhang, J.H., Chung, T.D. & Oldenburg, K.R. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 4, 67-73 (1999).
53. Johnston, P.A. et al. HTS identifies novel and specific uncompetitive inhibitors of the two-component NS2B-NS3 proteinase of West Nile virus. Assay Drug Dev. Technol. 5, 737-750 (2007).
54. Johnston, P.A. et al. Development and implementation of a 384-well homogeneous fluorescence intensity high-throughput screening assay to identify mitogen-activated protein kinase phosphatase-1 dual-specificity protein phosphatase inhibitors. Assay Drug Dev. Technol. 5, 319-332 (2007).
55. Rhode, H. et al. An improved method for checking HTS/uHTS liquid-handling systems. J. Biomol. Screen. 9, 726-733 (2004).